In the second episode of "The Biotech Pulse" our General Partner, Nanna Lüneborg, PhD, MBA, engages in a discussion with François Ravenelle, PhD, the Chief Executive Officer of Inversago Pharma. The backdrop to this conversation is the noteworthy acquisition of Inversago by Novo Nordisk for over $1 billion in August 2023. Together, Nanna and François explore the intricate landscape of mergers and acquisitions (M&A) within the biotech industry. The dialogue delves into the significance of showcasing market potential and fostering continuous business development with potential pharmaceutical partners.

The conversation unravels the essential steps biotechs must take to ensure preparedness for future licensing and collaboration opportunities with pharmaceutical giants. We dissect the criteria for gauging the 'readiness' of biotech assets for the pharmaceutical market and probe into the stress-testing processes adopted by pharma entities with an emphasis on the valuable guidance venture capitalists can provide to aid biotechs in achieving a successful exit. Join us as we navigate these critical aspects, shedding light on strategies for long-term success in the dynamic realm of mergers and acquisitions within the biotech sector.

See omnystudio.com/listener for privacy information.